Ashley Hallock, a 35-year-old patient, has found new hope after joining a stem cell clinical trial for bipolar disorder at UTHealth Houston. Describing the day she joined as the most important of her life, Ashley shared her struggles with depression and the challenges she faced in daily activities, such as publishing her photography book. Diagnosed with bipolar depression, traditional medications offered no relief.
Bipolar disorder is marked by shifts in mood and energy that impact daily functioning. According to research from 2023, around 8 million Americans are affected by this condition. The clinical trial at UTHealth Houston involves a double-blind, randomized, placebo-controlled study using allogeneic mesenchymal stem cells derived from adult bone marrow donors. These cells are manufactured in UTHealth's Judith R. Hoffberger Cellular Therapeutics Laboratory.
Dr. Jair Soares of UTHealth Houston stated that mesenchymal stem cells might offer innovative therapy for treatment-resistant bipolar depression due to their ability to counteract inflammation and promote neurogenesis. He explained that these cells could potentially reduce brain inflammation linked to mood fluctuations.
UTHealth Houston has previously published studies indicating stem cells' potential to dampen inflammation associated with bipolar disease. Dr. Soares highlighted the institution's strong stem cell program and collaboration with researchers in pediatric neurosurgery and neurology.
The clinical trial remains double-blind; thus, Ashley is unaware if she received the actual treatment or a placebo. However, she reported feeling better since participating in the study, noting improved energy levels and an enhanced ability to maintain her routine.
